Biotech investor Cormorant secures $150M for another SPAC deal [Yahoo! Finance]
Helix Acquisition prices $150M initial public offering [Seeking Alpha]
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by analysts at Raymond James Financial, Inc. to a "moderate buy" rating.
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)